<DOC>
	<DOCNO>NCT01466504</DOCNO>
	<brief_summary>Skin toxicity frequently observe side effect era `` molecularly targeted therapy '' . Skin toxicity follow administration protein kinase inhibitor sorafenib , regorafenib , lapatinib , sunitinib , others debilitate patient , result dose reduction discontinuation treatment . The mechanisms skin toxicity induce targeted chemotherapy , sorafenib regorafenib , poorly understood . Further research warrant good understand pathophysiology drug-related skin toxicity set develop correction strategy . This study test hypothesis sorafenib regorafenib interfere p63 expression keratinocyte differentiation skin remodel . Eligible study participant evaluate clinically evidence skin toxicity visit outpatient Oncology clinic . Study participant undergo skin biopsy sorafenib regorafenib treatment initiated rash develop 12 week treatment sorafenib regorafenib . Skin biopsy perform Oncology clinic study investigator clinic support staff . Study participant undergo skin biopsy regardless whether develop rash . In patient develop rash representative lesion biopsied . A normal appear area skin biopsied participant develop rash .</brief_summary>
	<brief_title>Effect Sorafenib Regorafenib P63 Expression Keratinocyte Differentiation Human Skin</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>1 . Male female , 18 year old old . 2 . Histologically cytologically confirm diagnosis solid tumor ( RCC , HCC , colorectal cancer ) . 3 . Participants plan initiate treatment either sorafenib regorafenib single chemotherapeutic agent 4 . Able swallow retain oral medication clinically relevant , active gastrointestinal disease condition may significantly alter absorption , distribution , metabolism , excretion drug . 5 . Be able provide write informed consent . Exclusion Criteria 1 . Patients receive chemotherapeutic molecularly target agent addition sorafenib regorafenib 2 . Concurrent moderate severe chronic inflammatory skin condition ( eczema , psoriasis ) 3 . Concurrent blister skin disorder severity ( pemphigus , bullous pemphigoid ) 4 . Connective tissue disorder skin involvement ( systemic lupus erythematosus , scleroderma , dermatomyositis , etc . ) 5 . Patients manifest allergic skin reaction ( urticaria ) skin reaction complication prior chemotherapy 6 . Patients skin lesion infectious noninfectious cause , preclude skin biopsy 7 . Patients willing undergo skin biopsy 8 . Patients pregnant plan become pregnant participation study . 9 . Chemotherapy , target therapy , biological therapy within two week start treatment . 10 . Ability give inform consent compromise cognitive and/or decisional impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>P63</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Regorafenib</keyword>
	<keyword>rash</keyword>
	<keyword>skin toxicity</keyword>
	<keyword>RCC</keyword>
	<keyword>HCC</keyword>
	<keyword>colorectal carcinoma</keyword>
</DOC>